Suggested Readings

Approach to the management of recently diagnosed inflammatory bowel disease patients: a user's guide for adult and pediatric gastroenterologists.

Agrawal M, et al. Gastroenterology. 2021;161(1):47-65.

STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.

Turner D, et al. Gastroenterology. 2021;160(5):1570-1583.

A treat-to-target update in ulcerative colitis: a systematic review.

Ungaro R, et al. Am J Gastroenterol. 2019;114(6):874-883.

From bench to bedside: fecal calprotectin in inflammatory bowel diseases clinical setting.

Mumolo MG, et al. World J Gastroenterol. 2018;24(33):3681-3694.

Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.

Sands BE, et al. N Engl J Med. 2019; 381(13):1215-1226.

Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease.

Patel H, et al. Crohn's Colitis 360. 2019;1(2):otz022.

Prediction of outcome of treatment of acute severe ulcerative colitis using principal component analysis and artificial intelligence.

Ghoshal UC, et al. JGH Open. 2020;4(5):889-897.

P025 Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North study.

Sandborn W, et al. Am J Gastroenterol. 2020;115(suppl 1):S6-S7.

FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.

US Food and Drug Administration. 2021.

The safety of vedolizumab for ulcerative colitis and Crohn's disease.

Colombel JF, et al. Gut. 2017;66(5):839-851.

Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies.

Sandborn WJ, et al. Inflamm Bowel Dis. 2021;27(7):994-1007.

Defining success in treating patients with inflammatory bowel disease.

Theede K, et al. Expert Rev Clin Immunol. 2017;13(7):645-647.

Related activities
1.50 AMA PRA

Optimizing Advanced Therapies in Ulcerative Colitis

Is Your Practice Up to Date? A Focus on Clinical Evidence and Guideline Recommendations

Faculty: Maria T. Abreu, MD; Jean-Frédéric Colombel, MD
Release: 10/15/2021
Expiration: 10/15/2022